# Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma

> **NCT05039892** · PHASE2 · NOT_YET_RECRUITING · sponsor: **3D Medicines (Beijing) Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Cholangiocarcinoma,Adult

## Interventions

- **DRUG:** 3D185

## Key facts

- **NCT ID:** NCT05039892
- **Lead sponsor:** 3D Medicines (Beijing) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05039892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05039892, "Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05039892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*